{
  "schema_version": "chamgap-public-criteria-1.0",
  "title": "Aged garlic extract 2.4-7.2 g/day × Reduction of ex vivo platelet aggregation",
  "language": "en",
  "translation_date": "2026-10-26",
  "criteria_version": "1.1",
  "criteria_date": "2026-10-05",
  "condition_origin": "Chamgap's own application conditions",
  "method_sources": [
    {
      "id": "M03",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2023-08",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-03",
      "section": "§3.1, §3.2.1–3.2.3, MECIR C5/C7/C13",
      "official_principle": "Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.",
      "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed."
    },
    {
      "id": "M04",
      "version": "Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-04",
      "section": "§4.5, §4.6.1–4.6.3, MECIR C42",
      "official_principle": "Distinguish studies from reports and link them; do not omit a study solely because results are unreported.",
      "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed."
    },
    {
      "id": "M08",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2019-10",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08",
      "section": "§8.1–8.2.3, Table 8.2.a",
      "official_principle": "Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.",
      "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed."
    },
    {
      "id": "M15",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2023-08",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-15",
      "section": "§15.2.4, §15.3.1–15.3.3",
      "official_principle": "Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.",
      "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed."
    },
    {
      "id": "M19",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2019-10",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-19",
      "section": "§19.1.2, §19.2.1–19.2.4",
      "official_principle": "Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.",
      "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed."
    }
  ],
  "status_dictionary": {
    "Met": "Limited verification of the retained identity, observation or scope required by this row. This is separate from clinical sufficiency or full-text certification.",
    "Partly verified": "Some facts needed by the question are known, while the stated analysis, population, formulation or denominator remains unverified.",
    "Unverified": "Direct information for this question is unverified in the retained scope. This does not mean an effect of 0, no studies, no harm or an unreviewed table.",
    "Not applicable": "A specific extension obligation lies outside the narrow question. This does not substitute for unread or unverified material.",
    "Not applicable (alias)": "A grey-display alias of Not applicable.",
    "Not read": "The external material was not directly read in the current work. This is separate from reading the retained local summary.",
    "Conflicting data": "Actual disagreement between reports under the same conditions. Differences between other questions alone do not establish conflict."
  },
  "requirements": [
    {
      "item_id": "N01",
      "question_type": "Evidence condition",
      "question": "Are the broad original claim and the PAF evidence-gap question distinguished?",
      "needed": "The original broad claim, derived boundary, target endpoint and change history.",
      "role": "Required",
      "role_reason": "The broad parent verdict is not automatically promoted to an agonist-specific effect.",
      "application_exception": "This question is neither a new clinical verdict nor an originally listed subclaim.",
      "criterion": "Preserve the original verdict claim and separately fix the question of direct AGE-versus-placebo evidence and formulation identity for PAF-induced aggregation.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "If the boundary changes, compare inclusion/exclusion for the broad original claim and derived comparison together."
    },
    {
      "item_id": "N02",
      "question_type": "Evidence condition",
      "question": "Is the 1995 garlic preparation in the PAF material identical to the AGE product?",
      "needed": "The 1995 original methods: product name, manufacture/extraction, SAC, ingredients/batch, and AGE product specifications.",
      "role": "Required",
      "role_reason": "The formulation-identity gap is central to directness.",
      "application_exception": "Garlic preparations, raw garlic, powder, oil, allicin, black garlic and isolated SAC are not assumed to be AGE.",
      "criterion": "Directly verify the 1995 preparation's identity, standardization and product, and its identity with AGE capsules.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "Compare each report's product specifications to establish formulation identity before assessing PAF eligibility."
    },
    {
      "item_id": "N03",
      "question_type": "Evidence condition",
      "question": "Are the PAF candidate's route, actual dose and intake verified?",
      "needed": "The PAF candidate's administration route, product/active amount, frequency, medication records and adherence criteria.",
      "role": "Required",
      "role_reason": "Doses for other agonists are not copied as PAF trial doses.",
      "application_exception": "Known broad AGE doses alone do not make the PAF dose partly verified.",
      "criterion": "Verify the actual route, product amount, active specification and intake/adherence of the selected oral AGE and PAF candidate.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "After fixing product identity, compare actual exposure with planned doses and analyses."
    },
    {
      "item_id": "N04",
      "question_type": "Evidence condition",
      "question": "Are the PAF candidate's actual population, baseline status and eligibility verified?",
      "needed": "The 1995 population/eligibility criteria, baseline table, medication/disease exclusions and actual analysis population.",
      "role": "Required",
      "role_reason": "A population label and direct eligibility are separate.",
      "application_exception": "This is not applied to antiplatelet co-users, thrombosis patients or all adults.",
      "criterion": "Verify the small-sample healthy-men clue alongside actual age, eligibility/exclusions, baseline platelet function and co-medication.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "Compare formulation and population conditions together to assess direct applicability to the selected question."
    },
    {
      "item_id": "N05",
      "question_type": "Evidence condition",
      "question": "Are the PAF candidate's intake duration and blood-draw/testing times verified?",
      "needed": "The PAF candidate's dosing/discontinuation schedule, blood-draw/testing times, washout and sequence.",
      "role": "Required",
      "role_reason": "Responses at different times are not combined into one effect.",
      "application_exception": "Durations from other AGE reports or platelet-recovery times are not newly substituted.",
      "criterion": "Link administration duration, discontinuation/washout, blood draw and testing times to the same PAF-response conditions.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "Link temporal order and testing time to original methods/results, keeping different times separate."
    },
    {
      "item_id": "N06",
      "question_type": "Evidence condition",
      "question": "Are the PAF endpoint clue and exact aggregation measure verified?",
      "needed": "PAF assay specimens, agonist concentration, equipment, maximum-aggregation/threshold definition and unit/direction.",
      "role": "Required",
      "role_reason": "The same endpoint name does not establish an identical result when measures or stimulation conditions differ.",
      "application_exception": "The highest-dose ADP threshold is not converted into a PAF measure.",
      "criterion": "Verify the PAF description, concentration, maximum aggregation/threshold/curve, unit, direction and assay conditions.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "Compare methods and result tables, linking only matching PAF measures."
    },
    {
      "item_id": "N07",
      "question_type": "Evidence condition",
      "question": "Are the 1995 opposing description and PAF-specific numerical results and intervals verified?",
      "needed": "The 1995 PAF-specific result tables, models/tests, effects/CI and product identity.",
      "role": "Required",
      "role_reason": "The opposing description is retained while exact result attribution is limited.",
      "application_exception": "No arbitrary P values, CI, effect of 0 or AGE-null verdict are created.",
      "criterion": "Separately verify the report-level no-significant-in-vivo-oral-effect result and PAF-specific effects, tests, intervals and AGE formulation identity.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "Extract results by agonist and compare formulation matching and test direction."
    },
    {
      "item_id": "N08",
      "question_type": "Evidence condition",
      "question": "Is a direct AGE-versus-placebo comparison result for PAF verified?",
      "needed": "Placebo-comparison methods, results and arm-specific analysis tables for PAF with verified AGE formulation.",
      "role": "Required",
      "role_reason": "A gap in direct results must also be retained in the table.",
      "application_exception": "Unverified information within the retained scope is not a conclusion that 0 studies exist worldwide.",
      "criterion": "Verify the actual placebo comparison and result for matching AGE product, population, PAF measure and time.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "Fix product identity and the PAF measure before assessing direct comparison material against eligibility criteria."
    },
    {
      "item_id": "N09",
      "question_type": "Evidence condition",
      "question": "Are the PAF candidate's blinding, allocation and co-intervention procedures verified?",
      "needed": "The 1995 original methods, allocation/concealment, baseline tables, co-interventions/rescue treatment and blinding material.",
      "role": "Required",
      "role_reason": "A design label does not resolve allocation or measurement problems.",
      "application_exception": "The double-blind label does not add randomization, a parallel design or absence of bias.",
      "criterion": "Verify the candidate's double-blind placebo design alongside actual allocation, concealment, co-interventions, rescue treatment and assessment blinding.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "Compare methods, baseline and co-intervention records for arm-specific differences that could explain PAF results."
    },
    {
      "item_id": "N10",
      "question_type": "Evidence condition",
      "question": "Were the 34-person AGE results kept separate from direct PAF results?",
      "needed": "S01's full agonist plans, result tables, specimen/population links and whether PAF was included.",
      "role": "Required",
      "role_reason": "Other favorable signals are not read as effects on the selected PAF response.",
      "application_exception": "Absence from the current summary does not establish non-reporting or non-measurement throughout the paper.",
      "criterion": "Retain partial collagen/epinephrine reductions and the weak highest-dose ADP threshold in their original report without transferring them to PAF.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "Compare planned agonists and result tables to distinguish PAF measurement, omission and non-planning."
    },
    {
      "item_id": "N11",
      "question_type": "Evidence condition",
      "question": "Are PAF allocation, measurement and analysis n and missingness verified?",
      "needed": "PAF-specific arm flowcharts, analysis populations, completion/missingness n and handling rules.",
      "role": "Required",
      "role_reason": "Another report's total is not transferred as the selected-response denominator.",
      "application_exception": "Exact n is not inferred from the small-sample label, and 34 and 595 are not added.",
      "criterion": "Verify the PAF candidate's arm-specific allocation/completion/measurement/analysis n, missingness handling and direct AGE analysis population.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "Link paper flow and assay-specific population tables to assess cross-use of denominators and selective losses."
    },
    {
      "item_id": "N12",
      "question_type": "Evidence condition",
      "question": "Are between/within-arm contrasts, models, variance and CI for the PAF estimate verified?",
      "needed": "PAF-specific analysis plans, estimates, variance/CI and the basis for an important difference.",
      "role": "Required",
      "role_reason": "Broad original axes do not provide individual PAF analyses or intervals.",
      "application_exception": "Non-significance is not interpreted as equivalence, and no new effects, CI or percentage of conditions met are calculated.",
      "criterion": "Verify the actual effect of interest, analysis method, adjustment, variance/CI and clinical-importance criteria for PAF.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "Compare the actual estimand and intervals with verified important-difference criteria without new calculations."
    },
    {
      "item_id": "N13",
      "question_type": "Evidence condition",
      "question": "Do prespecified PAF endpoints, times and analyses agree with published results?",
      "needed": "Original registration/protocols, PAF plans, multiplicity rules, result tables and change history.",
      "role": "Required",
      "role_reason": "Material is needed to assess possible favorable selection among multiple agonists and doses.",
      "application_exception": "Unobtained registration is not converted into confirmed non-registration or selective reporting.",
      "criterion": "Verify planned PAF concentrations/measures, doses, times, analyses and multiplicity handling against published reports.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "Compare initial plans and agonist-specific published results, distinguishing planning, omission and changes."
    },
    {
      "item_id": "N14",
      "question_type": "Evidence condition",
      "question": "Are overall review results and the directly eligible PAF/AGE subset verified?",
      "needed": "Review included-trial tables, results by product/agonist/time/analysis and overlap tables.",
      "role": "Required",
      "role_reason": "Review averages or positive-report counts are not counted as direct replication.",
      "application_exception": "The 6 positive reports are not read as 6 positive PAF trials, and heterogeneity is not recalculated as PAF conflict.",
      "criterion": "Distinguish the broad review record of 12 RCTs, 595 people and 6 positive/rest-null trials from AGE/PAF-specific products, measures and trial results.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "Separate included trials by formulation and agonist, comparing both positive and no-difference results."
    },
    {
      "item_id": "N15",
      "question_type": "Evidence condition",
      "question": "Is overlap between the same AGE trial and review-included trials verified?",
      "needed": "Review included-trial tables, registration/paper identifiers, recruitment sites/periods and product/endpoint links.",
      "role": "Required",
      "role_reason": "The same 34 people or the review's 595 people are not recounted as independent participants.",
      "application_exception": "No 34+595 total or dose/agonist-specific independent-trial counts are automatically created.",
      "criterion": "Retain S01's multiple doses/agonists as the same 34-person context and verify S02 identity and overlap between S03 included trials and reports.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "Build report-trial-population-endpoint links to connect multiple reports and review recitations to the same families."
    },
    {
      "item_id": "N16",
      "question_type": "Evidence condition",
      "question": "Is independent replication under matching AGE/PAF conditions verified?",
      "needed": "Unique-trial results with verified formulation/PAF conditions and study-family links.",
      "role": "Required",
      "role_reason": "Broad original independence labels are not inherited by the individual selected response.",
      "application_exception": "Current unverified status does not establish 0 studies or an AGE effect of 0.",
      "criterion": "Verify unique direct replication results for matching formulation, population, PAF measure, comparison and time.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "Fix direct eligibility before comparing results and condition differences across unique study families."
    },
    {
      "item_id": "N17",
      "question_type": "Evidence condition",
      "question": "Are each report's funding clues and product/author independence verified?",
      "needed": "Original reports' funding/COI, product provision, authors/institutions/patents and included-trial tables.",
      "role": "Supplementary; required for independence claims",
      "role_reason": "Unverified funding is not converted into independent support or absence of bias.",
      "application_exception": "Product support alone does not automatically exclude results, and generic English funding wording is not treated as actual verification.",
      "criterion": "Retain unverified S01 product-support details, unverified S02 funding and S03 academic/mixed funding, and verify the PAF candidate's product/author/COI relationships.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "Compare funding and product/author relationships report by report, retaining unverified independence."
    },
    {
      "item_id": "N18",
      "question_type": "Evidence condition",
      "question": "Are bleeding events, collection, denominators and timing under the same exposure verified?",
      "needed": "Exposure with matching formulation: AE definitions, collection/severity, event/person counts, exposure/follow-up, discontinuation and comparisons.",
      "role": "Supplementary; required for harm claims",
      "role_reason": "Statements that clinical events were not measured differ from personal bleeding safety.",
      "application_exception": "Unverified bleeding is not written as 0 events or safety, and 34/595 are not reused as harm denominators.",
      "criterion": "Distinguish aggregation assays from actual bleeding, severe and discontinuation event definitions, collection, exposed/event participants, comparisons and follow-up.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "Separate aggregation results from safety populations/follow-up and compare events, timing and denominators."
    },
    {
      "item_id": "N19",
      "question_type": "Evidence condition",
      "question": "Are the original bleeding warning and direct co-medication/vulnerable-group data verified?",
      "needed": "Group-specific formulation, exposure, events, follow-up/alternative explanations and warning sources.",
      "role": "Supplementary; required for the stated safety claim",
      "role_reason": "Experimental trial-population results are not extended to special-population safety.",
      "application_exception": "Retaining a warning is neither new harm-causality/incidence adjudication nor a dosing prescription.",
      "criterion": "Distinguish original warnings for anticoagulants/antiplatelets, bleeding disorders and perioperative use from direct exposure/events, alternative causes and interaction material.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "Compare original warning evidence and group-specific safety material separately without certifying personal safety."
    },
    {
      "item_id": "N20",
      "question_type": "Evidence condition",
      "question": "Does the PAF response answer thrombosis prevention or aspirin replacement?",
      "needed": "A separate event question's definition, comparator, follow-up, denominator and clinical results.",
      "role": "Supplementary; required only for clinical extensions",
      "role_reason": "Experimental aggregation assays and clinical prevention are different questions.",
      "application_exception": "Not applicable does not mean no events, a PAF effect of 0 or safety certification.",
      "criterion": "Separate the selected ex vivo response gap from clinical thrombosis/bleeding and treatment-replacement questions.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "If an event question is requested, review separate clinical endpoints and long-term/event-follow-up studies."
    },
    {
      "item_id": "N21",
      "question_type": "Evidence condition",
      "question": "Are optimal dose, long-term persistence and special subgroups part of this question?",
      "needed": "If extension is requested: direct PAF dose comparisons, follow-up and prespecified subgroup/interaction material.",
      "role": "Supplementary; required only for extension claims",
      "role_reason": "A narrow gap question does not impose every extension study.",
      "application_exception": "The highest-dose signal for another agonist does not establish the optimal PAF dose.",
      "criterion": "Distinguish direct PAF identity/result gaps from dose optimization, discontinuation/long-term and subgroup questions.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "After direct PAF conditions are verified, assess eligible designs/results for each separate extension question."
    },
    {
      "item_id": "N22",
      "question_type": "Evidence condition",
      "question": "Were local-summary reading and unread linked external materials distinguished?",
      "needed": "Subsequent material-specific access/acquisition/reading records, versions, original locations and physical material.",
      "role": "Required",
      "role_reason": "Bibliographic existence is not promoted to full-text reading or acquisition of eligible results.",
      "application_exception": "Unattempted external access is not called access failure, and report-level historical full-text access is not inherited by a constructed DOI gateway.",
      "criterion": "Distinguish reading all 3 evidence entries, 3 citations and Korean/English text from unattempted, unacquired and unread external PubMed/DOI/full-text material by material.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "In authorized subsequent review, record external acquisition/reading as separate events and compare with retained summaries."
    },
    {
      "item_id": "N23",
      "question_type": "Evidence condition",
      "question": "Were the original review date, correction date and individual access dates distinguished?",
      "needed": "Historical material-specific access/version records and complete before/after correction versions.",
      "role": "Required",
      "role_reason": "A global review date is not an individual external access date.",
      "application_exception": "Historical agonist-separation wording is not converted into current original-paper reading.",
      "criterion": "Distinguish the original review-date field 2026-09-08, correction date 2026-09-14 and current review time; retain absent material-specific access-date/level fields as unrecorded.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "Link and compare original review, correction and actual access events separately."
    },
    {
      "item_id": "N24",
      "question_type": "Evidence condition",
      "question": "Are search/selection records available to verify the complete current PAF/AGE evidence?",
      "needed": "Historical queries/dates, selection/exclusion, unpublished/correction/retraction checks and product/agonist-specific candidate logs.",
      "role": "Required",
      "role_reason": "An absence statement requires an actual reviewed scope.",
      "application_exception": "0 new searches are not reported as 0 PAF studies or a complete current review.",
      "criterion": "Verify queries, dates, selection/exclusion, unpublished/correction-check logs and the scope of complete current evidence for the PAF/AGE question. Separately display current retained-summary reading and the absence of new searching.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "In an authorized separate update, fix the product/PAF question, reproduce the search scope and compare potentially omitted candidates."
    },
    {
      "item_id": "N25",
      "question_type": "Evidence condition",
      "question": "Were the original broad C46, axes and all results distinguished from a derived grade?",
      "needed": "The complete original summary, input identity, boundary/verdict/correction events and separate-grade policy.",
      "role": "Required",
      "role_reason": "The historical broad parent verdict does not become an individual efficacy status for the selected response.",
      "application_exception": "Unverified actual observations are not filled with the number 0 or no effect.",
      "criterion": "Retain original 3066 C46/axes/Warning, values, empty separate-claim list, generic English wording and corrections; state that the separate PAF grade is unrecorded.",
      "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.",
      "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.",
      "proposed_research": "Compare complete original text, preserved case values and change events to check that no new derived verdict was created."
    }
  ]
}